Treatment of metastatic colorectal Cancer Aflibercept/FOLFIRI can be widely used in the second Therapy Line

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷 / 06期
关键词：
FLUOROURACIL; LEUCOVORIN; IRINOTECAN; PLACEBO;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：358 / 358
页数：1
相关论文
共 50 条
  • [41] EFICACY AND SAFETY OF FOLFIRI-BEVACIZUMAB FOR THE SECOND-LINE TREATMENT OF METASTATIC COLORECTAL CARCINOMA
    Odabas, H.
    Ozdemir, N.
    Oksuzoglu, B.
    Abali, H.
    Kos, F. T.
    Babacan, N.
    Civelek, B.
    Uncu, D.
    Zengin, N.
    ANNALS OF ONCOLOGY, 2010, 21 : 218 - 218
  • [42] A prospective study of FOLFIRI plus aflibercept as second-line treatment after failure of FOLFOXIRI plus bevacizumab in patients with unresectable/metastatic colorectal cancer (CRC): EFFORT study
    Satake, Hironaga
    Ando, Koji
    Yasui, Hisateru
    Negoro, Yuji
    Kinjo, Tatsuya
    Yuge, Koutarou
    Baba, Kenji
    Orita, Hiroyuki
    Hirata, Keiji
    Shimokawa, Mototsugu
    Makiyama, Akitaka
    Saeki, Hiroshi
    Oki, Eiji
    Baba, Hideo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Second-line systemic therapy for metastatic colorectal cancer
    Mocellin, Simone
    Baretta, Zora
    Roque i Figuls, Marta
    Sola, Ivan
    Martin-Richard, Marta
    Hallum, Sara
    Cosp, Xavier Bonfill
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (01):
  • [44] Irinotecan in second-line therapy of metastatic colorectal cancer
    Jäger, E
    Jäger, D
    Orth, J
    Knuth, A
    ONKOLOGIE, 2000, 23 : S15 - S17
  • [45] IROX as second-line therapy for metastatic colorectal cancer
    Sobrero, Alberto
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (05) : 248 - 250
  • [46] IROX as second-line therapy for metastatic colorectal cancer
    Alberto Sobrero
    Nature Reviews Clinical Oncology, 2009, 6 : 248 - 250
  • [47] Efficacy of ramucirumab in combination with second-line or salvage-line FOLFIRI in patients with metastatic colorectal cancer
    Katata, Y.
    Nagasaka, T.
    Tanioka, H.
    Nyuya, A.
    Toshima, T.
    Mori, Y.
    Shigeyasu, K.
    Okawaki, M.
    Yamamura, M.
    Tsuruta, A.
    Ueno, T.
    Yamaguchi, Y.
    ANNALS OF ONCOLOGY, 2018, 29 : 33 - 33
  • [48] Safety and effectiveness of aflibercept plus FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): OZONE secondary analyses
    Chau, I.
    Fakih, M. G.
    Garcia-Alfonso, P.
    Linke, Z.
    Ruiz-Casado, A.
    Polo Marques, E.
    Picard, P.
    Celanovic, M.
    Cartwright, T.
    ANNALS OF ONCOLOGY, 2019, 30 : 227 - 227
  • [49] Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
    Peeters, Marc
    Oliner, Kelly S.
    Price, Timothy J.
    Cervantes, Andres
    Sobrero, Alberto F.
    Ducreux, Michel
    Hotko, Yevhen
    Andre, Thierry
    Chan, Emily
    Lordick, Florian
    Punt, Cornelis J. A.
    Strickland, Andrew H.
    Wilson, Gregory
    Ciuleanu, Tudor E.
    Roman, Laslo
    Van Cutsem, Eric
    He, Pei
    Yu, Hua
    Koukakis, Reija
    Terwey, Jan-Henrik
    Jung, Andre S.
    Sidhu, Roger
    Patterson, Scott D.
    CLINICAL CANCER RESEARCH, 2015, 21 (24) : 5469 - 5479
  • [50] Targeted Therapy for Metastatic Colorectal Cancer: Role of Aflibercept
    Mitchell, Edith P.
    CLINICAL COLORECTAL CANCER, 2013, 12 (02) : 73 - 85
12345